In vivo anti-tumor activity of armed ATC when co-injected with tumor cells to prevent the tumor development or when injected intratumorally into xenograft model of prostate cancer, armed ATC persist in Beige/SCID mice for 91 days in the spleen and bone marrow without interleukin-2 (IL-2) support [8,11]. This evidence concerns the gene IL2 and prostate carcinoma.